CGAS and Parkinson disease: The loss of cGAS in PD mice leads to the blockade of LCN, and a significant downregulation of P161NK4a, p-STING, and p-p65 expression, while significantly improving the behavior of MPTP-treated mice and reversing dopamine (DA) levels in PD model mice.